Decatur, IL, USA.
School of Medicine and Public Health Department of Psychiatry, University Health Services, University of Wisconsin, Madison, WI, USA.
Phys Sportsmed. 2022 Feb;50(1):84-92. doi: 10.1080/00913847.2021.1881841. Epub 2021 Feb 8.
There is overlap between the typical age of onset of bipolar disorder (BD) and the age of peak athletic success. Additionally, eating disorders (EDs) are prevalent psychiatric disorders in athletes. Despite the relevance of both disorders in this population, there remains a need for treatment guidelines, especially when present as comorbidities given the complex interplay between them.
This report provides background information and utilizes a case report to explore the presentation and treatment of BD comorbid with an ED in an athlete. It specifically highlights the case of an elite female long-distance runner utilizing a multidisciplinary approach specific to the patient's unique needs as an athlete.
Treatment of this elite athlete utilized strategic pharmacotherapy taking into consideration her training and competition cycles. At 16 week follow-up, the patient was psychiatrically stable, experienced improvement in her running and felt confident in choosing to stay on medication and continue her running career.
It is important for providers who work with high-level athletes to provide treatment choices that allow athletes to safely and successfully continue their sport while adequately treating their mental illness. Treatment guidelines that increasingly take into consideration complex psychiatric comorbidities and nuanced pharmacologic approaches are needed in order to advance the field of sports psychiatry.
双相情感障碍(BD)的典型发病年龄与运动巅峰年龄有重叠。此外,饮食失调(ED)是运动员中常见的精神疾病。尽管这两种疾病在该人群中都很常见,但仍需要治疗指南,特别是在这些疾病同时存在时,因为它们之间存在复杂的相互作用。
本报告提供了背景信息,并通过病例报告探讨了运动员中同时存在 BD 和 ED 的表现和治疗。它特别强调了一名精英女性长跑运动员的案例,该运动员采用了针对其运动员独特需求的多学科方法。
对这位精英运动员的治疗采用了策略性的药物治疗,考虑到她的训练和比赛周期。在 16 周的随访中,患者的精神状态稳定,跑步表现有所改善,并且对选择继续服药和继续她的跑步生涯充满信心。
对于与高水平运动员合作的医务人员来说,提供治疗选择很重要,这些选择可以让运动员安全且成功地继续他们的运动,同时充分治疗他们的精神疾病。为了推进运动精神病学领域,需要制定越来越多地考虑复杂精神共病和细微药物治疗方法的治疗指南。